Axis-MedTech First Transaction

Home >> Press Releases >> Axis-MedTech First Transaction

London, United Kingdom – 22nd May, 2025 Axis-MedTech is pleased to announce that  we have secured for our Ablatus Limited subsidiary the assets, goodwill, intellectual  property and associated knowhow of Ablatus Therapeutics. 

About Ablatus Ltd 

Ablatus Ltd specialise in Dual-Modality Tissue Ablation. A novel, non-thermal ablation  technology that combines electrical and chemical energy to treat soft tissue tumours with greater precision and safety. 

Unlike conventional thermal ablation methods, this dual-modality approach avoids  collateral damage to surrounding structures, making it ideal for complex or previously  inoperable cases. 

The platform is poised to address unmet needs in oncology, particularly for hard-to-reach  or temperature-sensitive treatment zones. 

Geoffrey Miller, Axis-MedTech Chairman commented “we are delighted to have  completed our first transaction and look forward to taking the business through to fulfil its  promise. 

This transaction aligns seamlessly with Axis-MedTech's long-term strategy by reinforcing  its commitment to identifying and developing high-potential medical technologies that  can drive meaningful advancements in patient care. 

Axis-MedTech was founded on the principle of addressing structural inefficiencies in the  Life Sciences sector - particularly by acquiring businesses with strong intellectual  property but limited strategic or financial resources. The addition of Ablatus Ltd reflects  this vision, as its dual-modality tissue ablation technology represents a highly innovative  approach to treating complex soft tissue tumours with greater precision and safety. 

By integrating Ablatus Ltd’s assets and expertise, Axis-MedTech can accelerate the  commercialisation of this groundbreaking technology while ensuring robust corporate  governance, strategic oversight, and disciplined capital management. This transaction  also signals Axis-MedTech’s intent to build a portfolio of high-impact health and wellness 

companies with global relevance, ultimately positioning itself as a leader in medical  innovation”. 

About Axis-MedTech 

Axis-MedTech was established to address a structural inefficiency within the Life  Sciences sector - where ground-breaking innovation and entrepreneurial energy often  outpace the development of the strategic frameworks needed to support long-term  growth. This dynamic presents a significant opportunity to contribute positively to the  ecosystem by providing the guidance, resources, and operational support that can help  promising ventures reach their full potential. In today’s environment, Axis-MedTech sees  an opportunity to partner with companies that possess exceptional intellectual property  but may benefit from enhanced strategic alignment and capital stewardship. Through  thoughtful collaboration and the application of decades of proven management  expertise, Axis aims to unlock value, empower key innovators, and build a portfolio of  globally impactful health and wellness businesses - for the benefit of all stakeholders. 

Contact : Geoff.miller@axis-medtech.com

Pioneering Innovation Across
MedTech, Biotech and Healthcare
© 2025 Axis MedTech Holdings Limited. All rights reserved. Axis MedTech Holdings Limited is a company registered in England and Wales. Company number 16297218. Registered address Welken House 10-11 Charterhouse Square, London, England, EC1M 6EH.